Next Article in Journal
Correction: Sarman, E.; Asci, H. Cellular Anti-Apoptotic Effects of Dapagliflozin in Methotrexate-Induced Liver Toxicity: Bax/Bcl-2/Cyt-C/Cas-9/Cas-3 Signaling Pathway. Int. J. Mol. Sci. 2026, 27, 2110
Previous Article in Journal
Development of One-Tube Multiplex Arbitrary (RAPD and ISSR) Marker-Based SCAR Assay for Simultaneous Detection and Authentication of Indian Senna (Senna alexandrina Mill.) and Its Adulterant Species
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611

1
Centre for Neuroscience Studies, Queen’s University, Kingston, ON K7L 3N6, Canada
2
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada
3
Department of Pediatrics, Queen’s University, Kingston, ON K7L 2V7, Canada
4
Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2026, 27(7), 3166; https://doi.org/10.3390/ijms27073166
Submission received: 17 January 2026 / Accepted: 27 January 2026 / Published: 31 March 2026
(This article belongs to the Section Molecular Genetics and Genomics)
In the original publication [1], there was a mistake in the legend for Figure 5. The mistake was the labelling of D and H separately in Figure 5. The slides are from the same pool of mice at 60 weeks of age, as they are better controls for any possible GM2 accumulation to be shown. The correct legend appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 5. Sections of the murine hypothalamus, thalamus, and amygdala were stained with an anti-GM2 antibody at 15× magnification. The brown spots on the images depict GM2 accumulation. A–C depicts the short-term, 20-week cohort: (A) GFP-injected Gm2a−/− mice; (B) ssAAV9-GM2A neonatally-injected Gm2a−/− mice; (C) ssAAV9-GM2A adult-injected Gm2a−/− mice; and (D,H) images from the same pool from disease-free heterozygous mice (Gm2a+/−) at 60 weeks. E–G depicts the long-term, 60-week cohort: (E) GFP-injected Gm2a−/− mice (n = 1), (F) ssAAV9-GM2A neonatally-injected Gm2a−/− mice, (G) ssAAV9-GM2A adult-injected Gm2a−/− mice. (I) In all sections of the brain at 20 weeks, Gm2a−/− mice treated with ssAAV9-GM2A have less accumulation than GFP-injected Gm2a−/− mice. Neonatally injected Gm2a−/− mice have much more accumulation in the hypothalamus than adult-treated Gm2a−/− mice. However, in the thalamus and amygdala, the adult-injected Gm2a−/− mice have notably more accumulation than the neonatally-injected Gm2a−/− mice. (J) In the thalamus and amygdala, ssAAV9-GM2A-treated mice have reduced accumulation compared to GFP-injected Gm2a−/− mice. However, in the hypothalamus, ssAAV9-GM2A adult-injected Gm2a−/− mice have substantially more GM2 than both neonatally-treated Gm2a−/− mice and GFP-injected Gm2a−/− mice. The black arrow indicates examples of areas saturated with GM2 accumulation.

Reference

  1. Vyas, M.; Deschenes, N.M.; Osmon, K.J.L.; Chen, Z.; Ahmad, I.; Kot, S.; Thompson, P.; Richmond, C.; Gray, S.J.; Walia, J.S. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vyas, M.; Deschenes, N.M.; Osmon, K.J.L.; Chen, Z.; Ahmad, I.; Kot, S.; Thompson, P.; Richmond, C.; Gray, S.J.; Walia, J.S. Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611. Int. J. Mol. Sci. 2026, 27, 3166. https://doi.org/10.3390/ijms27073166

AMA Style

Vyas M, Deschenes NM, Osmon KJL, Chen Z, Ahmad I, Kot S, Thompson P, Richmond C, Gray SJ, Walia JS. Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611. International Journal of Molecular Sciences. 2026; 27(7):3166. https://doi.org/10.3390/ijms27073166

Chicago/Turabian Style

Vyas, Meera, Natalie M. Deschenes, Karlaina J. L. Osmon, Zhilin Chen, Imtiaz Ahmad, Shalini Kot, Patrick Thompson, Chris Richmond, Steven J. Gray, and Jagdeep S. Walia. 2026. "Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611" International Journal of Molecular Sciences 27, no. 7: 3166. https://doi.org/10.3390/ijms27073166

APA Style

Vyas, M., Deschenes, N. M., Osmon, K. J. L., Chen, Z., Ahmad, I., Kot, S., Thompson, P., Richmond, C., Gray, S. J., & Walia, J. S. (2026). Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. Int. J. Mol. Sci. 2023, 24, 14611. International Journal of Molecular Sciences, 27(7), 3166. https://doi.org/10.3390/ijms27073166

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop